Peptide Drug Regulations: Citation and Traceability

Data Characteristics

Peptide drug regulations and SOP documents originate from regulatory bodies like the National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA). They also come from internal Quality Management System (QMS) documents. Update frequencies vary. Regulatory guidelines may be revised annually. Internal SOPs update based on process optimization or external audit requirements. Documents are typically in PDF format, containing specialized terminology, flowcharts, tables, and hyperlinks. Common fields and units include batch numbers, production dates, expiration dates, storage conditions (e.g., 2-8℃), purity (e.g., ≥98.0%), impurity limits (e.g., ≤0.5%), and analytical method parameters like High-Performance Liquid Chromatography (HPLC) retention times (in minutes) and detection wavelengths (in nm).

Constraints on Citation and Traceability

The specialized nature, update frequency, and structure of peptide drug regulatory documents impose specific requirements on citation and traceability. First, extensive specialized terminology and cross-references demand accurate context recognition from the RAG system. This prevents semantic loss from improper segmentation. Second, revisions to regulations and SOPs require citations to align with the latest versions. Outdated information can lead to compliance risks. Therefore, the system needs version management capabilities. Third, complex PDF layouts, especially tables and flowcharts, can cause information loss or formatting issues during text extraction, affecting recall quality. For example, a key parameter in a peptide purification SOP might be in a table or flowchart. Failure to extract and link this information accurately prevents providing a complete citation. Additionally, precise numerical values and units, such as a 100 μg/mL concentration requirement, demand exact recall. Any deviation in values or units can lead to misinterpretation.

Configuration Settings

Configuration Item	Recommended Value	Rationale
`Chunk size` (Segment Length)	`500–800 characters` (characters)	Ensures critical information (e.g., a complete process step or regulatory clause) is not split, while preventing overly long segments from introducing noise.
`Chunk Overlap Length` (Segment Overlap Length)	`100 characters` (characters)	Maintains contextual continuity, especially in peptide drug texts with extensive specialized terminology and complex sentence structures.
`Recall count` (Recall Count)	`Top 5–8 entries` (top 5–8 entries)	Balances recall comprehensiveness with RAG inference efficiency. Peptide drug regulations often require more context for complex questions.
`Similarity threshold` (Similarity Threshold)	`0.78–0.85`	Ensures the precision of recalled content, preventing fuzzy matching from introducing irrelevant regulations or SOP clauses.
`Rerank result count` (Rerank Return Count)	`Top 3 entries` (top 3 entries)	Further refines recall results, placing the most relevant regulations or SOP clauses first to improve user experience.
`PARSE_FILE_TIMEOUT_SECONDS`	`600 seconds` (seconds)	Peptide drug regulatory documents are often large and complex, requiring longer parsing times to avoid timeout failures.

Common Pitfalls

Symptom: The system returns citation links to old or invalid regulatory documents after a user query. Reason: The knowledge base is not updated with the latest versions of peptide drug regulations and enterprise SOPs, or a version management mechanism is missing.
Symptom: Cited content in RAG results differs from the original text, or critical numerical values and units are incorrect. Reason: PDF document parsing failed to correctly identify text within tables or images, or extracted text was not effectively cleaned and structured.
Symptom: Adjusting Recall count (Recall Count) and Similarity threshold (Similarity Threshold) does not significantly change the quantity or quality of recall results. Reason: The vector database's indexing strategy or the embedding model's understanding of peptide drug terminology may be insufficient, limiting recall. This is not solvable by simple parameter adjustments.

Verification Steps

Select typical questions from peptide drug R&D, production, and quality control. Manually compare system-returned citations against original sources to verify accuracy.
Regularly track the latest regulations and guidelines from NMPA, FDA, and other agencies. Check if relevant documents in the knowledge base are updated and test if the system correctly cites new versions.
For regulatory documents with complex layouts, including tables and flowcharts, verify that the system extracts text completely and logically. Pay close attention to critical parameters and numerical values.
Randomly sample citations provided by the system in actual use. Perform a word-by-word comparison with original documents to evaluate the Similarity threshold (Similarity Threshold) setting, ensuring both precision and completeness of recall.

The values provided are common starting points. Measure them against your own samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.